We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.56%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABUS icon
101
Arbutus Biopharma
ABUS
$861M
$650K 0.01%
180,582
– –
CMRX
102
DELISTED
Chimerix, Inc.
CMRX
$628K 0.01%
115,216
– –
BDSI
103
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$588K 0.01%
210,021
– –
FPRX
104
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$580K 0.01%
19,247
– –
BIVV
105
DELISTED
Bioverativ Inc. Common Stock
BIVV
$496K ﹤0.01%
8,249
– –
CCXI
106
DELISTED
ChemoCentryx, Inc.
CCXI
$459K ﹤0.01%
49,064
– –
TARA icon
107
Protara Therapeutics
TARA
$218M
$455K ﹤0.01%
7,465
– –
ADAP
108
DELISTED
Adaptimmune Therapeutics
ADAP
$449K ﹤0.01%
100,000
– –
TMBR
109
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$287K ﹤0.01%
40
+15
+60% +$131K
AIXC
110
AIxCrypto Holdings Inc
AIXC
$13.7M
$220K ﹤0.01%
3
– –
TENX icon
111
Tenax Therapeutics
TENX
$410M
$98K ﹤0.01%
+4
New +$66.6K
BGMSP
112
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$82K ﹤0.01%
13,253
– –
BTX.WS
113
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$7K ﹤0.01%
20,084
– –
BIIB icon
114
Biogen
BIIB
$30.6B
– –
-16,500
Closed -$4.51M
ACOR
115
DELISTED
Acorda Therapeutics
ACOR
– –
-27,515
Closed -$69.3M
DERM
116
DELISTED
Dermira, Inc.
DERM
– –
-415,448
Closed -$14.2M
WINT
117
DELISTED
Windtree Therapeutics Inc
WINT
– –
-254,973
Closed -$291K
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2017 Portfolio in Review

As of Q2 2017, Baker Bros. Advisors held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Baker Bros. Advisors added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Baker Bros. Advisors's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Baker Bros. Advisors fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Baker Bros. Advisors opened 6 new positions and closed 4 in Q2 2017.
  • Baker Bros. Advisors's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.